The library will be closed between August 10, 2026 and August 16, 2026. During this period, it will be possible to upload publications, but all other services will be suspended.
Venglovecz, V.,
Grassalkovich, A.,
Tóth, E.,
Ébert, A.,
Gál, E.,
Korsós, M. M.,
Maléth, J.,
Rakonczay, Z.,
Galla, Z.,
Monostori, P.,
Hegyi, P.:
Restoring CFTR function with Orkambi decreases the severity of alcohol-induced acute pancreatitis.
J. Physiol.-London. 602 (22), 6153-6170, 2024.
Ébert, A.,
Gál, E.,
Tóth, E.,
Szögi, T.,
Hegyi, P.,
Venglovecz, V.:
Role of CFTR in diabetes-induced pancreatic ductal fluid and HCO3- secretion.
J. Physiol.-London. 602 (6), 1065-1083, 2024.
Papp, H.,
Tóth, E.,
Bóvári-Biri, J.,
Bánfai, K.,
Juhász, P.,
Mahdi, M.,
Russo, L. C.,
Bajusz, D.,
Sipos, A.,
Petri, L.,
Szalai, T. V.,
Kemény, Á.,
Madai, M.,
Kuczmog, A.,
Batta, G.,
Mózner, O.,
Vaskó, D.,
Hirsch, E.,
Bohus, P.,
Méhes, G.,
Tőzsér, J.,
Curtin, N.,
Helyes, Z.,
Tóth, A.,
Hoch, N. C.,
Jakab, F.,
Keserű, G. M.,
Pongrácz, J.,
Bai, P.:
The PARP inhibitor rucaparib blocks SARS-CoV-2 virus binding to cells and the immune reaction in models of COVID-19.
Br. J. Pharmacol. 181 (23), 4782-4803, 2024.
Tóth, E.,
Maléth, J.,
Závogyán, N.,
Fanczal, J.,
Grassalkovich, A.,
Erdős, R.,
Pallagi, P.,
Horváth, G.,
Tretter, L.,
Bálint, E. R.,
Rakonczay, Z.,
Venglovecz, V.,
Hegyi, P. J.:
Novel mitochondrial transition pore inhibitor N-methyl-4-isoleucine cyclosporin is a new therapeutic option in acute pancreatitis.
J. Physiol.-London. 597 (24), 5879-5898, 2019.
